Lunesta Starting Dose
The recommended starting dose of Lunesta (eszopiclone) is 2 mg immediately before bedtime for most non-elderly adults, 1 mg for elderly patients whose primary complaint is difficulty falling asleep, and 2 mg for elderly patients whose primary complaint is difficulty staying asleep. 1
Dosing Algorithm by Patient Population
Non-Elderly Adults (18-64 years)
- Start at 2 mg immediately before bedtime 1
- May increase to 3 mg if clinically indicated, as the 3 mg dose is more effective for sleep maintenance 1
- The 2 mg and 3 mg doses were the basis for guideline recommendations showing moderate-to-large improvements in sleep quality 2
Elderly Patients (≥65 years)
The starting dose depends on the primary sleep complaint:
For difficulty falling asleep (sleep onset insomnia): Start at 1 mg 1
- May increase to 2 mg if clinically indicated 1
For difficulty staying asleep (sleep maintenance insomnia): Start at 2 mg 1
Special Populations Requiring Dose Reduction
Start at 1 mg (do not exceed initially) in:
- Patients with severe hepatic impairment 1
- Patients taking potent CYP3A4 inhibitors (can increase to 2 mg if needed) 1
No dose adjustment needed for:
- Renal dysfunction 5
Clinical Evidence Supporting These Doses
The American Academy of Sleep Medicine guidelines (2017) specifically recommend eszopiclone based on trials using 2 mg and 3 mg doses, showing 2:
- Sleep onset latency: 12-minute improvement over placebo
- Wake after sleep onset: 10-14 minute reduction
- Total sleep time: 28-57 minute increase
- Sleep quality: Moderate-to-large improvement
Important Administration Considerations
Avoid taking with or immediately after a heavy, high-fat meal 1 - this slows absorption and reduces effectiveness on sleep latency.
Common Adverse Effects to Counsel Patients About
The most frequently reported adverse events include 2, 6, 7:
- Unpleasant taste (most common - occurs in ~18% more patients than placebo)
- Dry mouth
- Dizziness
- Somnolence
- Headache
These effects are generally mild and well-tolerated, with eszopiclone demonstrating a favorable safety profile in trials up to 12 months duration 3, 7.
Critical Safety Caveat
While eszopiclone is effective for both sleep onset and maintenance, observational data suggest hypnotics may be associated with increased risk for dementia, fractures, and major injury in long-term use 8. The FDA has documented risks for cognitive and behavioral changes, including driving impairment 8. Exercise increased caution in elderly individuals with cognitive or motor impairments 7.